Comparative Pharmacology
Head-to-head clinical analysis: DUONEB versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUONEB versus VESICARE LS.
DUONEB vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUONEB is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist). Ipratropium inhibits muscarinic acetylcholine receptors in bronchial smooth muscle, reducing vagal tone and bronchodilation. Albuterol stimulates beta-2 adrenergic receptors, leading to relaxation of bronchial smooth muscle.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
1-2 vials (2.5 mg ipratropium bromide/2.5 mg albuterol sulfate per 3 mL vial) via nebulization every 6 hours as needed; maximum 6 vials per day.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Ipratropium: terminal half-life ~2 hours (range 1.5-4 hours). Albuterol: terminal half-life 3.8-6 hours (mean ~4.6 hours). Clinical context: Both contribute to bronchodilation lasting 4-6 hours.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
DuoNeb (ipratropium bromide/albuterol sulfate) is a fixed-dose combination. Ipratropium: 90% excreted unchanged in feces (biliary), <10% renal. Albuterol: 60-70% renal as unchanged drug and metabolites (sulfate conjugate), 30-40% fecal.
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category C
Category C
Anticholinergic/Beta2-Agonist Combination
Anticholinergic